Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 6, 2012, Pages 395-402

  Golan, Yoav ^a   Epstein, Lauren ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile; Fidaxomicin; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; FIDAXOMICIN; LFF 571; METRONIDAZOLE; NITAZOXANIDE; OP 1118; PLACEBO; RIFAXIMIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE INFECTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HELMINTHIASIS; HUMAN; HYPERURICEMIA; LEUKOPENIA; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTOZOAL INFECTION; RECURRENT INFECTION; REVIEW; SIDE EFFECT; VOMITING;

EID: 84868222353     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12461294     Document Type: Review

References (44)

1. Abrahamian F. Talan D. Moran G. Pinner R. (2006) Update on emerging infections from the Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. Ann Emerg Med 48: 55–59.
2. Ackermann G. Loffler B. Adler D. Rodloff A. (2004) In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 48: 2280–2282.
3. Al-Nassir W. Sethi A. Li Y. Pultz M. Riggs M. Donskey C. (2008) Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52: 2403–2406.
4. Babakhani F. Gomez A. Robert N. Sears P. (2011) Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 55: 4427–4429.
5. Bartlett J. (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346: 334–339.
6. Bartlett J. (2008) The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 46: 1489–1492.
7. Biedenbach D. Ross J. Putnam S. Jones R. (2010) In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 54: 2273–2275.
8. Bignardi G. (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40: 1–15.
9. Centers for Disease Control and Prevention (2005) Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. MMWR Morbid Mortal Wkly Rep 54: 1201–1205.
10. Citron D. Tyrrell K. Merriam C. Goldstein E. (2012) Comparative in vitro activities of LFF 571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 56: 2493–2503.
11. Cohen S. Gerding D. Johnson S. Kelly C. Loo V. McDonald L. et al. Society for Healthcare Epidemiology of America & Infectious Diseases Society of America (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431–455.
12. Cornely O. Crook D. Esposito R. Poirier A. Somero M. Weiss K. et al. OPT-80-004 Clinical Study Group (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12: 281–289.
13. Coronelli C. White R. Lancini G. Parenti F. (1975) Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot 28: 253–259.
14. Credito K. Appelbaum P. (2004) Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 48: 4430–4434.
15. Dubberke E. Wertheimer A. (2009) Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 30: 57–66.
16. Finegold S. Molitoris D. Vaisanen M. Song Y. Liu C. Bolanos M. (2004) In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 48: 4898–4902.
17. Freeman J. Baines S. Todhunter S. Huscroft G. Wilcox M. (2011) Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. J Antimicrob Chemother 66: 1407–1408.
18. Garey K. Ghantoji S. Shah D. Habib M. Arora V. Jiang Z. et al. (2011) A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 66: 2850–2855.
19. Gerber M. Ackermann G. (2008) OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Exp Opin Invest Drugs 17: 547–553.
20. Ghantoji S. Sail K. Lairson D. Du Pont H. Garey K. (2010) Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 74: 309–318.
21. Golan Y. Louie T. Miller M. Mullane K. Weiss K. Lentnek A. et al. (2011) Risk of recurrence and time to recurrence following treatment of Clostridium difficile infection: patient characteristics and the differential effect of fidaxomicin vs. vancomycin. Presented at Digestive Disease Week, 7–10 May 2011, Chicago, I.L., USA.
22. Goldstein E. Citron D. Sears P. Babakhani F. Sambol S. Gerding D. (2011) Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 55: 5194–5199.
23. Gualtieri M. Villain-Guillot P. Latouche J. Leonetti J. Bastide L. (2006) Mutation in the Bacillus subtilis RNA polymerase beta’ subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 50: 401–402.
24. Hecht D. Galang M. Sambol S. Osmolski J. Johnson S. Gerding D. (2007) In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51: 2716–2719.
25. Johnson S. (2009) Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 58: 403–410.
26. Karlowsky J. Laing N. Zhanel G. (2008) In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 52: 4163–4165.
27. Kelly C. La Mont J. (2008) Clostridium difficile – more difficult than ever. N Engl J Med 359: 1932–1940.
28. Louie T. Emery J. Krulicki W. Byrne B. Mah M. (2009 a) OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53: 261–263.
29. Louie T. Miller M. Donskey C. Mullane K. Goldstein E. (2009 b) Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 53: 223–228.
30. Louie T. Miller M. Mullane K. Weiss K. Lentnek A. Golan Y. et al. OPT-80-003 Clinical Study Group (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422–431.
31. McDonald L. Killgore G. Thompson A. Owens R. Kazakova S. Jr Sambol S. et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433–2441.
32. McDonald L. Owings M. Jernigan D. (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 12: 409–415.
33. Mullane K. Miller M. Weiss K. Lentnek A. Golan Y. Sears P. et al. (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53: 440–447.
34. Musher D. Aslam S. Logan N. Nallacheru S. Bhaila I. Borchert F. Hamill R. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40: 1586–1590.
35. Optimer Pharmaceuticals (2011) Dificid (fidaxomicin) package insert. San Diego, CA.
36. Pepin J. Valiquette L. Alary M. Villemure P. Pelletier A. Forget K. et al. (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171: 466–472.
37. Schwan C. Stecher B. Tzivelekidis T. van Ham M. Rohde M. Hardt W. et al. (2009) Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 5: no. e 100062610.
38. Shue Y. Sears P. Shangle S. Walsh R. Lee C. Gorbach S. et al. (2008) Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 52: 1391–1395.
39. Swanson R. Hardy D. Shipkowitz N. Hanson C. Ramer N. Fernandes P. et al. (1991) In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 35: 1108–1111.
40. Tannock G. Munro K. Taylor C. Lawley B. Young W. Byrne B. et al. (2010) A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156: 3354–3359.
41. Traynor K. (2011) Fidaxomicin approved for C. difficile infections. Am J Health System Pharm 68: 1276.
42. Tupin A. Gualtieri M. Leonetti J. Brodolin K. (2010) The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site. EMBO J 29: 2527–2537.
43. Venuto C. Butler M. Ashley E. Brown J. (2010) Alternative therapies for Clostridium difficile infections. Pharmacotherapy 30: 1266–1278.
44. Zar F. Bakkanagari S. Moorthi K. Davis M. (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302–307.